ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Is a Good Night's Sleep at the Top of Your Wishlist?

Ashwagandha Helps Hormones - Aids Arthritis

A Breathalyzer for Disease?

Why You Should Be Eating More Porcini Mushrooms

Tryptophan's Possible Effects for Your Health

How Bacopa Can Help Improve Your Cognitive Function

Black Tea Is Great for Your Gut

Magnesium Reduces Diabetes and Helps Keep You Young

Lavender Aromatherapy Can Ease Pre-Op Anxiety

Mint: Learn More About This Refreshing and Invigorating Herb

 
Print Page
Email Article

How Analysts See the Fibromyalgia Drug Market Unfolding

  [ 9 votes ]   [ Discuss This Article ]
www.ProHealth.com • October 12, 2011


The diagnosed and drug-treated FM population is expected to grow by 1.7 million persons by 2020, according to a recent news release by the market analyst firm Decision Resources Group. But, barring new & improved drug entries, the FM-specific prescription drug market will ‘only’ grow by $200 million (from $1.6 billion to $1.8 billion each year by 2020) as receipts for two branded drugs approved by the FDA for prescription to fibromyalgia patients – Cymbalta and Lyrica – start to be ‘eroded’ by sale of generic (non-branded and thus less expensive) versions of the drugs.

Taking up some of the slack from generic erosion of Cymbalta and Lyrica will be predicted increases in sales of the branded drugs Savella (aka milnacipran), Nycynta ER (tapentadol ER) and Lyrica (pregabalin). Helped of course by the basic growth in the diagnosed patient population.

Other facts in the report are that the US accounted for 80% of the $1.6 billion fibromyalgia drug market in 2010, and should account for about two-thirds of the $1.8 billion market in 2020. One wild card is that “ample opportunity” remains for new prescription therapies that could improve on the efficacy and tolerability of the current leading FDA-approved drugs.




Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Mitochondria Ignite™ with NT Factor® Ultra EPA  - Fish Oil


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Complete and Natural Menopause Relief Complete and Natural Menopause Relief
Health Benefits Are Brewing in Green Tea Health Benefits Are Brewing in Green Tea
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Strontium - The Missing Mineral for Strong Bones Strontium - The Missing Mineral for Strong Bones
How I Found My Long-Lost Energy How I Found My Long-Lost Energy

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map